HLA Class I Expressions on Peripheral Blood Mononuclear Cells in Colorectal Cancer Patients

作     者：Zhi-mian Zhang Xiao Guan Ying-jie Li Ming-chen Zhu Xiao-jing Yang Xiong Zou 

作者机构：Department of Health Examination CenterQilu HospitalShandong UniversityJinan 250012China Department of Clinical Laboratory MedicineQilu HospitalShandong UniversityJinan 250012China 

出 版 物：《Chinese Journal of Cancer Research》 (中国癌症研究（英文版）)

年 卷 期：2012年第24卷第1期

页      面：77-82页

核心收录：

学科分类：0710[理学-生物学] 1007[医学-药学(可授医学、理学学位)] 090602[农学-预防兽医学] 100705[医学-微生物与生化药学] 07[理学] 09[农学] 0906[农学-兽医学] 071005[理学-微生物学] 10[医学] 

基　　金：supported by Shandong Province Natural Science Foundation (No. Y2008C104) Shandong Province Science Foundation for Key Program (No. 2007GG20002027,2008GG2NS02016 and 2009GG10002043) 

主　　题：HLA class I Peripheral blood mononuclear cells RT-PCR Flow cytometry Colorectal cancer 

摘      要：Objective： To investigate the expression change of human leukocyte antigen （HLA） class I on human peripheral blood mononuclear ceils （PBMCs） at both mRNA and protein levels, and to evaluate its roles in the development of colorectal cancer （CRC）. Methods： In the present study, 50 patients with CRC, 35 patients with benign colorectal lesion and 42 healthy volunteers were enrolled. Expression levels of HLA class I mRNA and protein were determined using real-time quantitative reverse transcription PCR （RT-PCR） and flow cytometry analysis, respectively. Results： The expression levels of HLA class I mRNA and proteins were not influenced by age and gender. The relative ratios of HLA class I mRNA were 0.99±0.27 in healthy controls, 0.76±0.19 in benign patients, and 0.48±0.21 in CRC patients. Mean fluorescence intensities of HLA class I were 145.58±38.14 in healthy controls, 102.05±35.98 in benign patients and 87.44±34.01 in CRC patients. HLA class I on PBMCs was significantly down-regulated at both mRNA and protein levels in patients with stage III and IV CRC. CRC patients with lymph node metastasis also showed a decreased HLA class I expression at protein level. Conclusion： HLA class I expressions on PBMCs are associated with staging of CRC and lymph node metastasis. Monitoring the expression of HLA class I on PBMCs may provide useful information for diagnosis and metastasis judgement of CRC.